Work

Impact de l’addiction au tabac sur la prise en charge des pathologies psychiatriques : point de vue pharmaceutique

Year: 2022
Type: dissertation
Abstract: The majority of patients with psychiatric illnesses will smoke cigarettes during their lifetime. Today, the health consequences of smoking are well known, but their impact on drug treatments remains unclear. Yet tobacco is composed of many chemicals, such as PAHs and nicotine, that interact with some of our cytochromes that are essential for proper drug metabolism. Pharmacology shows many interactions between tobacco and various psychotropic drugs, which can lead to changes in concentrations. Indeed, it has an enzymatic inducing effect on cytochromes 1A1, 1A2, 2E1 and potentially 2D6. Thus, the molecules metabolized by the latter will see their biotransformation accelerated and will thus be eliminated more quickly. All families of psychotropic drugs seem to be concerned, with the exception of thymoregulators. However, an adaptation of the dosage is not obligatory and must be based on the clinical situation, taking into account a change in smoking habits and possible dosages which could show modifications of the concentrations. Today, it is necessary to raise awareness of this concept among all health professionals who supervise these patients, as well as the patients themselves, to ensure optimal management. Prevention through different actions is a key point to work on in order to limit the potential consequences. The town pharmacist has a central role that could be reinforced by the implementation of a meeting on tobacco and psychotropic drugs, promoting the role of health actor that patients are looking for today.
Source: HAL
Author: Grenouillet, Camille
Language: English
Subfield: Pharmacology
Open Access status: green
OpenAlex ID: W6982322389
Cites:
Cited by:
Related to: 10